Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Neurocrine Biosciences Inc

+ Add to Watchlist

NBIX:US

33.6600 USD 0.6900 2.01%

As of 20:10:00 ET on 01/30/2015.

Snapshot for Neurocrine Biosciences Inc (NBIX)

Open: 34.2000 Day's Range: 33.6200 - 35.0000 Volume: 985,294
Previous Close: 34.3500 52wk Range: 12.1700 - 35.0000 1-Yr Rtn: +96.96%

Stock Chart for NBIX

No chart data available.
  • NBIX:US 33.6600
  • 1D
  • 1M
  • 1Y
34.3500
Interactive NBIX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NBIX

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7418
Est. EPS (USD) (12/2014) -0.7900
Est. PEG Ratio -
Market Cap (M USD) 2,558.33
Shares Outstanding (M) 76.01
30 Day Average Volume 1,380,223
Price/Book (mrq) 11.4179
Price/Sale (ttm) 3,105.2964
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NBIX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NBIX

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.

Kevin C GormanPresident/CEOTimothy P CoughlinChief Financial Officer
Christopher F O'BrienChief Medical OfficerHaig P BozigianChief Development Officer
More Company Profile & Key Executives for NBIX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil